Related Experiment Video
Updated: Jun 3, 2026
09:15
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Dynamics of long-term statin therapy
Maarit Jaana Korhonen1, Arja Helin-Salmivaara, Risto Huupponen
1Department of Pharmacology, Drug Development and Therapeutics, University of Turku, 20014, Turun yliopisto, Finland. maarit.korhonen@utu.fi
European Journal of Clinical Pharmacology
|March 17, 2011
Summary
Statin therapy use is dynamic, with nearly half of patients discontinuing treatment. Many patients reinitiate statins, highlighting the need to consider usage patterns in clinical practice.
Area of Science:
- Pharmacology
- Public Health
- Epidemiology
Background:
- Long-term statin therapy usage patterns are not well understood.
- Characterizing statin use is crucial for accurate incidence and outcomes research.
Purpose of the Study:
- To analyze statin use patterns, including reinitiation after discontinuation.
- To examine adherence transitions and the impact of drug-free periods on new user identification.
Main Methods:
- Utilized Finnish prescription data (1997-2007) for individuals aged 45-84 initiating statins.
- Employed survival analysis for reinitiation rates after ≥180 days of non-use.
- Calculated annual adherence and prevalence of good/poor adherence over ten 1-year periods.
Main Results:
- 48.1% of 32,760 initiators discontinued statins for ≥180 days.
- 46.7% of discontinuers restarted within 1 year; 88.7% by end of follow-up.
- 51.8% achieved ≥6 years of good adherence over ≥10 years; 27.7% of new users in 2007 had prior refills.
Conclusions:
- Statin utilization is dynamic and characterized by frequent discontinuations and reinitiations.
- Clinical practice and research on statin incidence, patterns, and outcomes must account for these dynamic usage patterns.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:05Steady State Concentration
A steady state refers to the level of a drug in the body once it has reached an equilibrium between administration and elimination. It represents the point at which the drug administration rate equals the drug elimination rate, resulting in a relatively constant concentration in the body over time. The dynamic equilibrium is crucial to ensure the drug's effectiveness with minimal risk of toxicity.
Most drugs are administered in repeated doses at fixed intervals or through continuous intravenous...
Most drugs are administered in repeated doses at fixed intervals or through continuous intravenous...
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:25Dosage Regimen: Multiple Oral Dosage
Understanding how a drug's concentration fluctuates within the body over time is crucial in pharmacokinetics, particularly with multiple oral doses. A graphical representation of multiple oral dosages provides insight into these dynamics. Typical accumulation curves of a drug's concentration in the body reveal a sawtooth pattern, indicating periodic peaks and troughs correlating with each dose administration and the drug's subsequent elimination.The plasma concentration at any time during an...